Official Title: “An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia”

To document effectiveness, safety, and tolerability of donepezil in patients with mixed AD/VaD, and to further document the effectiveness, safety, and tolerability of donepezil in patients with VaD. The effects of donepezil on executive functioning, behavior, general cognition, ADLs and global functioning will be assessed.

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study

Study Primary Completion Date: April 2008

The trial was terminated on October 15, 2007 due to difficulties in recruiting the subjects.

There were no safety or efficacy concerns regarding the study medication in the decision to terminate the trial.

Intervention(s) in this Clinical Trial

• Drug: Donepezil
  • donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1

Primary Measures

• Change in Total Score of Standardized Mini-Mental State Examination sMMSE); (All Subjects)
  • Time Frame: Baseline, week 12, week 24
    Safety Issue?: No

Secondary Measures

• Disability Assessment for Dementia Change From Baseline; Activities of Daily Living (ADL) Domain.
  • Time Frame: Baseline, week 12, week 24
    Safety Issue?: No
• Disability Assessment for Dementia Change From Baseline; Instrumental ADL (IADL) Domain.
  • Time Frame: Baseline, 12 weeks, 24 weeks
    Safety Issue?: No
• Disability Assessment for Dementia Change From Baseline; FAS Population (All Subjects)(DAD)Total Score Change.
  • Time Frame: Baseline, week 12, week 24
    Safety Issue?: No
• Free-Hand Drawing Test (CLOX 1) Change From Baseline; FAS Population (All Subjects)
  • Time Frame: Baseline, 12 weeks, 24 weeks
    Safety Issue?: No
• Copied Clock Drawing Test (CLOX 2) Change From Baseline; (All Subjects)
  • Time Frame: Baseline, 12 weeks, 24 weeks
    Safety Issue?: No
• CLOX Differential Score Change From Baseline; FAS Population (All Subjects)
  • Time Frame: Baseline, 12 weeks, 24 weeks
    Safety Issue?: No
• Phonectic Fluency Total Score From Baseline; FAS Population (All Subjects)
  • Time Frame: Baseline, 12 weeks, week 24
    Safety Issue?: No
• Neuropsychiatric Inventory Questionnaire (NPI-Q) Score Change From Baseline; FAS Population (All Subjects)
  • Time Frame: Baseline, 12 weeks, 24 weeks
    Safety Issue?: No
• Neuropsychiatric Inventory Questionnaire Distress (NPI-Q-D) Score Change From Baseline; FAS Population (All Subjects)
  • Time Frame: Baseline, week 12, week 24
    Safety Issue?: No
• Clinical Global Impressions Severity Score (CGI-S) Clinical Global Impressions Severity Score Improvement(CGI-I)Change From Baseline, FAS Population
  • Time Frame: Baseline, week 24
    Safety Issue?: No
• Clinical Global Impressions Severity (CGI-S)
  • Time Frame: Baseline
    Safety Issue?: No
• Clinical Global Impressions Improvement (CGI-I)
  • Time Frame: Week (wk) 24
    Safety Issue?: No
• Clinical Global Impressions Improvement (CGI-I) Dichotomized Response
  • Time Frame: Baseline, week 24
    Safety Issue?: No

Inclusion Criteria:

• Subjects must meet DSM-IV-TR criteria for the clinical diagnosis of Vascular Dementia or the clinical diagnosis of dementia due to multiple etiologies.
• Subjects must have a reliable caregiver or family member who agrees to accompany the subject to all scheduled visits, provide information about the subject as required.

Exclusion Criteria:

• Subjects with any current primary psychiatric diagnosis other than dementia of the Alzheimer's type or Vascular Dementia.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 50 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Pfizer

Overall Clinical Trial Officials and Contacts

Pfizer CT.gov Call Center Study Director Pfizer  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00174382

Study ID Number: A2501026

ClinicalTrials.gov Identifier: NCT00174382

Health Authority: Canada: Health Canada

To obtain contact information for a study center near you, click here.

Link to ClinicalStudyResults.org Posting